公开(公告)号：US12178813B2

公开(公告)日：2024-12-31

申请号：US17139299

申请日：2020-12-31

Applicant: Nxera Pharma UK Limited

Inventor： John Andrew Christopher ,  Miles Stuart Congreve ,  Sarah Joanne Bucknell ,  Francesca Deflorian ,  Mark Pickworth ,  Jonathan Stephen Mason

IPC: A61K31/496 ,  C07D241/14 ,  C07D401/14 ,  C07D471/04 ,  C07D498/10 ,  C07D498/20

Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

公开(公告)号：US12227521B2

公开(公告)日：2025-02-18

申请号：US17617851

申请日：2020-06-12

Applicant: Nxera Pharma UK Limited

Inventor： Giles Albert Brown ,  Miles Stuart Congreve ,  Stephen Paul Watson ,  Julie Cansfield ,  Michael Alistair O'Brien ,  Francesca Deflorian ,  Gregory R. Ott ,  Nigel Alan Swain ,  Andrew David Cansfield

IPC: C07D498/22

Abstract: The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

公开(公告)号：US12202843B2

公开(公告)日：2025-01-21

申请号：US17345557

申请日：2021-06-11

Applicant: Nxera Pharma UK Limited

Inventor： Miles Stuart Congreve ,  Giles Albert Brown ,  Benjamin Gerald Tehan ,  Mark Pickworth ,  Julie Elaine Cansfield

IPC: C07D519/00 ,  A61K31/438 ,  A61K31/439 ,  A61P25/00 ,  A61P25/18 ,  A61P25/28 ,  C07D471/10 ,  C07D498/10

Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where m, p, q, W, Z, Y, X1, X2, R1, R2, R3 and R4 are as defined herein.

公开(公告)号：US12054472B2

公开(公告)日：2024-08-06

申请号：US17239137

申请日：2021-04-23

Applicant: Nxera Pharma UK Limited

Inventor： Miles Stuart Congreve ,  Stephen Philippe Andrews ,  Jonathan Stephen Mason ,  Christine Mary Richardson ,  Giles Albert Brown

IPC: A61K31/506 ,  A61K31/4427 ,  A61K31/53 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5386 ,  C07D253/07 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

CPC classification number: C07D401/04 ,  A61K31/4427 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5386 ,  C07D253/07 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor. A process for the preparation of the compound, pharmaceutical compositions comprising the compound, and methods of treatment comprising administration of an effective amount of the compound are also disclosed.

公开(公告)号：US12234227B2

公开(公告)日：2025-02-25

申请号：US17285776

申请日：2019-10-21

Applicant: NXERA PHARMA UK LIMITED

Inventor： Giles Albert Brown ,  Miles Stuart Congreve ,  Barry John Teobald ,  Charlotte Fieldhouse ,  Nigel Alan Swain ,  Mark Pickworth ,  Giovanni Bottegoni

IPC: C07D403/14 ,  C07D401/14 ,  C07D471/04 ,  C07D487/04

Abstract: Novel compounds of formula (1): and salts thereof, wherein A; X; n; R1 and R2 are defined herein, are disclosed, as well as their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.

公开(公告)号：US12215099B2

公开(公告)日：2025-02-04

申请号：US17311212

申请日：2019-12-09

Applicant: Nxera Pharma UK Limited

Inventor： Giles Albert Brown ,  Miles Stuart Congreve ,  Benjamin Gerald Tehan ,  Mark Pickworth

IPC: C07D413/14 ,  C07D471/08

Abstract: This invention related to compounds having activity as muscarinic M1 or M1 and M4 receptor agonists which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where X1; X2; X3; X4; Y; Z; n, R1 and R2 are defined herein.

公开(公告)号：US20240376070A1

公开(公告)日：2024-11-14

申请号：US18689590

申请日：2022-09-15

Applicant: NXERA PHARMA UK LIMITED

Inventor： Stephen Paul WATSON ,  Nigel Alan SWAIN ,  Michael Alistair O'BRIEN

IPC: C07D401/04 ,  A61K31/4439 ,  A61K31/675 ,  C07F9/6558

Abstract: The disclosures herein relate to novel compounds of Formula (1a) or (1b) or a salt thereof, wherein R1, R2, R3, R4, R8, R9 and R10 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR52 receptors.